1. Denmark Stocks

  2. •

    Health technology

  3. •

    Medical specialties
ViroGates A/S

ViroGates A/S

CCPH:VIRO
8.00
DKK
0.00
(0.00%)
-0.87EPS
101.17MMarket Cap
Nov 05Next Earn
ViroGates A/S
CPH:VIRO
(Nasdaq Copenhagen)

Recent

price

8.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
DKK
0.99
0.85
0.97
0.91
1.34
2.02
4.67
2.02
1.07
1.13
1.08
Revenue per Share
-1.45
-2.09
-4.97
-4.78
-4.69
-4.32
-2.96
-3.49
-2.15
-1.32
-0.87
Basic EPS, GAAP
-1.79
-2.22
-4.79
-4.73
-3.93
-5.24
-4.39
-3.52
-1.79
-0.52
-1.4
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.28
0.76
15.52
10.74
7.73
4
3.71
2.64
1.4
2.09
1.75
Book Value per Share
2.28
0.76
15.52
10.74
7.73
4
3.71
2.64
1.4
2.09
1.75
Tangible Book Value per Share
4
3
3
4
4
4
3
3
7
8
9
Basic Weighted Avg Shares
4
2
3
4
5
8
15
7
7
9
9
Sales/Revenue/Turnover
-188.2
-315.03
-546.06
-550.61
-368.49
-227.83
-71.36
-179.82
-203.86
-117.61
-91.26
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-5
-6
-17
-19
-19
-18
-10
-12
-14
-10
-8
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-146.58
-245.27
-512.4
-524.76
-349.94
-214.17
-63.47
-173.12
-200.85
-116.77
-80.81
Profit Margin (%)
9
3
61
42
31
16
16
22
15
23
19
Working Capital
- -
- -
- -
- -
- -
- -
- -
5
4
3
3
LT Debt
9
3
61
42
31
16
16
17
11
19
16
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-99.92
-53.07
-36.42
-50.96
-74
-59.33
-73.1
-103.19
-68.86
-72.15
Return on Common Equity (%)

Capital Structure

DKK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
1
1
LT Borrowings
3
3
3
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
9
Market Capitalization
125
99
101

Working Capital

DKK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
30
27
22
Cash, Cash Equivalents & STI
26
22
18
Accounts Receivable, Net
1
1
- -
Inventories
2
2
1
Total Current Liabilities
8
7
3
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

DKK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-0.13%
79.74%
Free Cash Flow
- -
-15.81%
-65.47%
Net Income, GAAP
- -
-6.93%
-27.52%
Sales/Revenue/Turnover
- -
22.23%
24.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

DKK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
1
3
2
7
2025
1
4
2
2
9
2026
1
4
- -
- -
- -

Quarterly Earnings Per Share

DKK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.56
-0.64
-0.35
-0.57
-2.15
2025
-0.36
-0.42
-0.25
-0.29
-1.32
2026
-0.28
-0.06
- -
- -
- -

Quarterly Dividends Per Share

DKK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
ViroGates A/S ViroGates A/S is a Denmark-based international in vitro diagnostics company that develops and markets proprietary blood tests under the suPARnostic® brand to measure the suPAR biomarker, which indicates chronic inflammation levels and predicts disease presence, severity, progression, and mortality risk across conditions including cardiovascular disease, type 2 diabetes, cancer, infectious diseases, kidney disease, and respiratory issues; the product line comprises suPARnostic® TurbiLatex for turbidimetric platforms compatible with leading analyzers from Roche, Siemens, Abbott, and Beckman Coulter, suPARnostic® Quick Triage for point-of-care testing, and suPARnostic® ELISA assays, enabling results in under 20 minutes to support patient triage in emergency departments, guide treatments such as sepsis and COVID-19 therapies, and monitor biological age and lifestyle interventions in health and longevity clinics. Founded in 2001 based on research from Hvidovre University Hospital and headquartered in Birkerød north of Copenhagen in Medicon Valley, the company operates sales forces in Spain, France, and Benelux while serving over 20 countries worldwide through distributors in Europe, North America, the Middle East, East Asia, Southeast Asia, and East Africa; it targets hospitals for acute care triage, clinical laboratories and health clinics for longevity and preventive health monitoring, and research institutions leveraging over 1,000 peer-reviewed publications on suPAR. Recent strategic developments include a October 2024 distribution agreement with SuPAR Health LLC to launch suPARnostic® ELISA as a lab-developed test in the US longevity market, accompanied by a directed share issuance of 1,289,510 shares to SuPAR Remedy LLC raising DKK 8.2 million; an agreement with GENSPEED Biotech GmbH to refine the suPARnostic® POC+ device for clinical use with results expected in H1 2025; ongoing collaboration with Swedish Orphan Biovitrum AB (Sobi) including a US FDA Q-Submission meeting in April 2024 to pursue 510(k)/De Novo clearance for suPARnostic® TurbiLatex; and a reorganization of the marketing and sales department to prioritize the health and longevity segment amid a 12% revenue decline to DKK 4.9 million in 2024.